Table 2 Clinical outcomes in atrial fibrillation patients who had active cancer.
From: Impact of type of anticoagulant on clinical outcomes in cancer patients who had atrial fibrillation
Patient-years | Number of event | Event rate (event/100 PY) | Unadjusted HR (95% CI) | aHR-MSM (95% CI) | |
|---|---|---|---|---|---|
Stroke | |||||
Warfarin | 1353 | 19 | 1.4 (0.9–2.2) | Reference | Reference |
DOAC | 471 | 9 | 2.7 (1.0–3.7) | 1.3 (0.6–3.0) | 0.8 (0.2–2.7) |
LMWH/UFH | 319 | 16 | 5.0 (3.1–8.2) | 3.1 (1.6–6.0) | 2.4 (1.0–5.6) |
GI-bleeding | |||||
Warfarin | 1217 | 47 | 3.8 (2.9–5.1) | Reference | Reference |
DOAC | 434 | 24 | 5.5 (3.7–8.2) | 1.4 (0.8–2.3) | 1.5 (0.9–2.6) |
LMWH/UFH | 276 | 23 | 8.3 (5.5–12.5) | 1.9 (1.2–3.2) | 1.2 (0.6–2.4) |
Intracranial bleeding | |||||
Warfarin | 1370 | 22 | 1.6 (1.0–2.4) | Reference | Reference |
DOAC | 492 | 6 | 1.2 (0.5–2.7) | 0.7 (0.3–1.8) | 0.8 (0.3–2.5) |
LMWH/UFH | 333 | 10 | 3.0 (1.6–5.6) | 1.7 (0.8–3.5) | 1.1 (0.4–3.1) |
Overall -bleeding | |||||
Warfarin | 973 | 112 | 11.5 (9.5–13.8) | Reference | Reference |
DOAC | 316 | 45 | 14.2 (10.6–19.0) | 1.2 (0.8–1.7) | 1.1 (0.7–1.6) |
LMWH/UFH | 197 | 49 | 24.8 (18.8–32.9) | 2.0 (1.4–2.8) | 1.1 (0.6–1.7) |
Death | |||||
Warfarin | 1419 | 57 | 4.0 (3.1–5.2) | Reference | Reference |
DOAC | 516 | 28 | 5.4 (3.7–7.8) | 1.4 (0.9–2.2) | 1.2 (0.7–2.2) |
LMWH/UFH | 349 | 50 | 14.3 (10.8–18.9) | 4.1 (2.7–6.1) | 4.5 (2.8–7.2) |
